Why Is Varex Imaging (VREX) Stock Up +0.11% Today?
Key Takeaways
- VREX shares edged up 0.11% to $18.51, versus a prior close of $18.49.
- The gain reflects consolidation just below Teledyne Technologies' $18.90-per-share cash acquisition offer rather than a fresh catalyst.
- Teledyne's roughly $1.1 billion all-cash takeover, announced August 10, continues to anchor the stock near the deal price.
- Varex's fiscal third-quarter results, which swung to a profit and beat earnings estimates, provide underlying fundamental support.
- Analysts have largely recalibrated to hold or neutral ratings as shares approach the takeover price.
- Traders are watching deal-closing milestones, regulatory approvals, and any competing bid for the company.
Opening Summary
Varex Imaging Corporation (VREX), a Salt Lake City-based designer and manufacturer of X-ray imaging components for the medical and industrial markets, closed up 0.11% on the session at $18.51, compared with a prior close of $18.49. The move was modest, and it reflects a stock that has settled into a tight range just below the $18.90 per share that Teledyne Technologies has agreed to pay in cash to acquire the company. Rather than any single breaking headline, the day's modest advance was driven by continued merger-arbitrage support and a fundamental backdrop bolstered by a stronger-than-expected fiscal third quarter.
Teledyne Acquisition Keeps a Floor Under the Stock
The dominant force behind the current price level is the definitive agreement announced on August 10, under which Teledyne Technologies (NYSE: TDY) agreed to acquire all outstanding shares of Varex Imaging for $18.90 per share in cash, valuing the transaction at approximately $1.1 billion. The offer represented a premium of more than 50% to Varex's prior closing price, and the announcement sent the stock surging roughly 48% in a single session.
Since then, shares have traded in a narrow band just below the offer price, a classic hallmark of a merger-arbitrage situation. With the cash consideration effectively setting a ceiling near $18.90 and deal completion still contingent on regulatory approvals and a Varex stockholder vote, the stock has limited room to run higher in the absence of a competing bid. The modest 0.11% gain reflects steady buying interest as investors position for the deal's expected completion in early 2027.
Strong Fiscal Third-Quarter Results Underpin the Re-Rating
Supporting the stock is a fundamentally improved operating picture. Alongside the acquisition announcement, Varex reported fiscal third-quarter results that swung to a net profit from a loss in the prior-year period. Total revenue rose to approximately $210 million from $203 million a year earlier, with industrial application revenue climbing to $76.5 million from $60.9 million, offsetting softer medical segment sales.
Non-GAAP earnings per share of $0.31 came in well ahead of consensus estimates near $0.21, while GAAP net income reached $15.7 million, or $0.37 per share, compared with a net loss of $89.1 million a year ago. The earnings beat helped reinforce the view that Teledyne is acquiring a business with improving cash generation, even as management withdrew financial guidance and canceled its earnings call while the acquisition is pending.
Analyst Recalibration Near the Deal Price
Following the announcement, the sell-side largely moved to the sidelines. Multiple firms downgraded Varex Imaging to hold, neutral, or market perform ratings, reasoning that with a firm cash offer in place, there is limited upside beyond the takeover price. One firm reaffirmed a neutral stance while lifting its price objective to $19, essentially in line with the $18.90 offer. The shift from buy to hold ratings is a common pattern in announced acquisitions and helps explain why the stock has consolidated rather than continuing to rally.
Market Context and Trading Activity
Trading volume on the session was roughly in line with the stock's recent average, consistent with a market that has already repriced the acquisition news. The shares have traded between $9.09 and $18.63 over the past year, meaning Varex Imaging is currently sitting near its 52-week high and just below the agreed deal price. The stock's trajectory has diverged sharply from the broader medical-device and X-ray equipment sector over the past month, a reflection of the deal-driven repricing rather than sector-wide momentum. Technically, the $18.90 offer level now acts as a hard resistance point, while merger-arbitrage demand has provided a stable floor near current levels.
What Comes Next for VREX
The path forward for VREX is now tied primarily to the acquisition timeline. Investors will watch for regulatory approvals, the filing and mailing of the proxy statement, and the scheduling of the special stockholder vote required to adopt the merger agreement. Any sign of a competing or superior proposal could prompt a reassessment of the current price, while delays or complications in the closing process could widen the spread between the market price and the $18.90 offer. With guidance withdrawn and the earnings call suspended during the pending transaction, the company's standalone quarterly reporting will carry less influence on the stock than deal-related milestones in the months ahead.
Trending AI Robots
For traders seeking a systematic approach to navigating events like the one unfolding in VREX, Tickeron's Trending AI Robots page highlights the platform's strongest-performing automated strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the bots demonstrating the most robust recent performance are curated into this featured section. Explore the Trending AI Robots page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
VREX sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for VREX moved above the 200-day moving average on August 18, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on VREX as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for VREX just turned positive on July 24, 2026. Looking at past instances where VREX's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VREX advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 153 cases where VREX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
VREX broke above its upper Bollinger Band on August 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VREX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.571) is normal, around the industry mean (11.035). P/E Ratio (34.925) is within average values for comparable stocks, (70.949). Projected Growth (PEG Ratio) (4.979) is also within normal values, averaging (4.006). VREX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.905) is also within normal values, averaging (34.463).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VREX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufactures of X-ray tubes, flat panel detectors, connectors and accessories for imaging as well as workstations and software for computer-aided diagnostics and image processing
Industry MedicalNursingServices
Advertisement